Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06059300
Other study ID # 114374
Secondary ID 1371055504021300
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date July 17, 2023
Est. completion date July 1, 2028

Study information

Verified date June 2023
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Digital breast tomosynthesis (DBT) creates a digital pseudo- three-dimensional image of the breast similar to mammography. This gives the screening radiologist more information about a possible abnormality. As a result, breast cancer can be found earlier, but more women might need to be recalled. In the STREAM study, the aim is to identify the impact of DBT on the screen-detected cancer and recall rates, and on interval and advanced cancer rates in 18,200 women after two rounds of screening. For comparison, a control group of about 86,400 women will be selected from the database of the national screening program. Women, screening radiographers, and screening radiologists will be asked whether they find this new screening technique acceptable. Furthermore, the optimal strategy for screening radiologists to read the DBT images will be identified and the cost-effectiveness of screening with DBT will be determined. The images and data will be stored in a database for future research. Expected outcome: As a result of this project, the researchers will have shown if breast cancer screening with DBT in the Netherlands should be implemented or not. It will also be demonstrated, were it to be introduced, how it should be implemented, having addressed all the remaining questions, and having found the optimal DBT workflow specifically for a high-volume population-based screening program.


Description:

In the last decade, several large-scale European studies have shown that digital breast tomosynthesis (DBT) increases the detection rate from ~6 to ~9 cancers per 1000 women screened, while the recall rate approaches 3.5% to 4%, independent of the initial recall rate. In the Dutch screening setting with digital mammography (DM), the recall rate is only 2.4%. Therefore, introducing DBT in the Netherlands will likely generate an increase in false positives, but the magnitude of this increase is unknown. Furthermore, the ~50x increase in the number of images resulting from a DBT exam compared to a DM exam doubles the reading time. For DBT screening in the Netherlands to be feasible from the economic and human resources point of view, the interpretation of these cases must be accelerated, to result in an average reading time comparable to that of reviewing DM exams. The aim of this project is to make the replacement of DM with DBT in the Dutch National Breast Cancer Screening Program feasible and sustainable, by ensuring its acceptability by the various stakeholders, optimizing the acquisition and reading strategy, determining its expected impact on the national recall rate, and determining its cost-effectiveness. In addition, completion of this project will result in the creation of a DBT-based screening database available for future research. Work Package (WP) 1 will involve the introduction of DBT in 6 of the 71 screening units in the country to screen 18,200 women for two screening rounds. This study is powered to detect a combined one-third reduction in the interval and advanced cancer rates with DBT screening as the primary endpoint. In addition, as secondary endpoints, the Dutch DBT-based screening recall rates will be determined for the first and second rounds of DBT screening. A contemporary control group of about 86,400 women screened with DM will be selected from the screening database (ScreenIT) of the national screening program. This control group will be selected to reflect the distribution of urban and rural areas as well as the mixture of mobile and fixed units of the screening units selected for the intervention group. In addition, the attendees, and the screening radiographers and radiologists will be surveyed to identify any barriers that limit acceptability of this new modality. Finally, WP1 will also involve the creation of a DBT-based screening database for further research. In WP2, the optimal DBT reading strategy to be used in the Dutch screening program to minimize the increase in reading time with DBT, will be identified. For this, retrospective observer studies will be performed, using the images from WP1, to test eight different acquisition and reading strategies, some involving the use of cutting-edge artificial intelligence computer systems. These strategies have been shown in initial studies, many performed by the sponsor, to result in a significant reduction in reading time, with no or minimal loss in performance. Once the optimal reading strategies is identified, it will be used to interpret the entire second round of DBT screening acquired in WP1 at the screening reading units retrospectively. In this way, its actual performance and impact on reading time in the real screening environment will be determined. Finally, in WP3, the results from the other two WPs will be used to model the entire DBT screening program and therefore predict the long-term outcomes and cost-effectiveness of this new screening program. The only method possible to estimate the impact of screening on long-term effects, such as breast cancer mortality and morbidity, as well as cost-effectiveness, is the use of modelling. Therefore, the well-validated MISCAN model will be used, with the data and results gathered, to estimate the long-term impact of DBT screening. As a result of this project, if successful, breast cancer screening with DBT will be ready for nationwide implementation, having addressed all the country-specific questions and having optimized the DBT workflow specifically for a high-volume population-based screening program.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 18200
Est. completion date July 1, 2028
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 72 Years
Eligibility Inclusion Criteria: - Women who are invited to participate to the Dutch Breast Cancer Screening program in the age group 50-72 years.. Exclusion Criteria: - Disabled women - Women who are wheelchair bound

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Digital Breast Tomosynthesis
Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds

Locations

Country Name City State
Netherlands Bevolkingsonderzoek Nederland Utrecht

Sponsors (13)

Lead Sponsor Collaborator
Radboud University Medical Center Dutch Breast Cancer Association, Dutch Foundation of Population Screening, Erasmus Medical Center, Hologic B.V., iCAD, LRCB Dutch Expert Centre for Screening, Lunit Inc., Screenpoint Medical BV, Sectra Benelux, UMC Utrecht, University of Sydney, Volpara Health Technologies Ltd

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The effect of DBT screening on breast cancers diagnosed at an advanced stage at screening or in between rounds of screening. (detection rate of stage II+ cancers per 1000 screens and interval cancer rate per 1000 screens) The outcome will be compared to the control group (DM) 5 years
Secondary Attendance rate (percentage out of all women invited) The outcome will be calculated for the intervention group (DBT) and the control group (DM): 5 years
Secondary Recall (percentage out of all women screened) The outcome will be calculated for the intervention group (DBT) and the control group (DM): 5 years
Secondary Cancer detection rate for breast cancer, both invasive and in situ, overall and for cancers stage II or higher (stage II+; per 1000 screened) The outcome will be calculated for the intervention group (DBT) and the control group (DM): 5 years
Secondary Positive predictive value for recall (percentage of cancers detected among recalled women) The outcome will be calculated for the intervention group (DBT) and the control group (DM): 5 years
Secondary Interval cancer rates (breast cancer detected clinically in the first, second, or third year after a negative screening examination. The outcome will be calculated for the intervention group (DBT) and the control group (DM): 5 years
See also
  Status Clinical Trial Phase
Completed NCT04601272 - Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions
Completed NCT03979729 - Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography
Completed NCT02198690 - Trial of a Mammography Decision Aid for Women Aged 75 and Older N/A
Completed NCT01885741 - Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy N/A
Completed NCT01267110 - Engaging Diverse Underserved Communities to Bridge the Mammography Divide N/A
Completed NCT00287040 - Breast Cancer Screening Via Computer V. Phone Phase 3
Recruiting NCT05268224 - A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue
Recruiting NCT06098118 - Adapting a Mammography Decision Aid to Support Women Living in a Community Contaminated by PFAS N/A
Completed NCT05821023 - Messaging Strategies to Reduce Breast Cancer Over-screening in Older Women N/A
Recruiting NCT05841355 - Empowering Latinas to Obtain Guideline Concordant Screenings N/A
Recruiting NCT05960188 - Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images N/A
Recruiting NCT04429269 - A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis
Active, not recruiting NCT03377036 - Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography N/A
Completed NCT05756725 - Improving Cancer Screening and Follow-up in Community Health Centers N/A
Completed NCT03046004 - Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making N/A
Completed NCT03517813 - CESM ABMR Breast Cancer Screening Trial
Completed NCT02273206 - Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women N/A
Completed NCT00224224 - A Comparison of Primary Care and Traditional Internal Medicine Residents N/A
Recruiting NCT04102722 - Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening N/A
Completed NCT04259866 - FALSE POSITIVE FINDINGS IN BREAST CANCER TOMOSYNTHESIS

External Links